The Hedge Book logo The Hedge Book Read smarter. Invest better.

AI Stock Monitor

AMGN - Amgen

Amgen is a North America covered company in The Hedge Book research universe.

Public company · North America · Healthcare · Biotechnology · Dow constituent

NASDAQ · Healthcare · Research updated · Market data updated Research and source refreshes run four times daily. The timestamps above identify the latest successful research and market-data updates.
Hedge Score 45 /100
BearishBearish
Confidence65%
Community Bullish0%
Followers0
Current Price$435.641D -0.7%

Price History

AMGN chart

466.01414.81363.62312.42261.22 Nov 2023May 2024Nov 2024May 2025Nov 2025May 2026Nov 2026 2023-11-20 265.462025-05-26 288.182026-11-20 435.64

AI-Assisted Chart Analysis

Amgen technical analysis

Calculated from verified chart history for the selected tenor; no news or fundamental assumptions are used.

Technical only
Trend

Mixed trend: the latest level is above its 20-period average, without full long-term confirmation.

Momentum

RSI is 49, a neutral reading. Above 70 can signal extension; below 30 can signal exhaustion.

Support scenario

The first technical watch zone is 366.29. A break below 290.13 invalidates the near-term support setup.

Resistance scenario

The first resistance/watch zone is 466.01. A confirmed break above 466.01 supports continuation.

Risk

Annualized realized volatility is +61.3%. Maximum lookback drawdown is -22.6%, from a high-water mark of 337.38 to 261.22.

Potential levels are conditional chart scenarios, not personalized advice or instructions to buy or sell.

How To Read This Stock Brief
Hedge Score

Higher means the current research setup is stronger across signal, confidence, catalysts, risk balance, and market context. Lower means the setup is weaker or less supported.

Confidence

Higher confidence means the evidence is more consistent and relevant. It does not mean the stock has that percentage chance of going up.

Signal

Bullish, Bearish, or Neutral is the current AI research stance. It is designed to help you ask better questions, not to replace your decision process.

Community Bullish

This shows how signed-in users are voting. It is useful sentiment context, not proof that the crowd is right.

Read the full Hedge Score and confidence methodology

What Changed Today

  • Yahoo Finance delayed market data reported AMGN at 435.64 USD; the latest daily move fell -0.72%. This is a verified market-price signal only and does not by itself confirm a change in company fundamentals.

Why It Matters

  • The verified -0.72% daily move is current market context for Amgen.
  • It can affect near-term sentiment, but price action alone does not establish a change in earnings, asset quality, competitive position, valuation, catalysts, or risks.
  • Those require a separately sourced filing or company update.

AI Opinion

  • Read: The current evidence-grounded AI read is bearish.
  • Evidence: The MariTide trial progression is a significant fundamental development that could drive future revenue growth, but it is still in the clinical phase, meaning commercial success is not guaranteed.
  • Uncertainty: The competitive threat to Tepezza from Viridian Therapeutics is a notable risk that warrants close monitoring, as it could impact the company's ability to sustain margins in its bone and inflammation health segments.
  • Watch: Investors should look for further updates on the MariTide trial data and any potential impact from the securities litigation settlement on the balance sheet.

Key Risks

  • Competitive erosion of the Tepezza franchise by new entrants like Viridian Therapeutics could lead to market share loss and margin pressure.
  • Clinical trial failure or delays for the MariTide program would significantly impair the company's growth prospects in the lucrative obesity market.
  • Ongoing legal and regulatory scrutiny, including the current securities litigation, poses a risk of financial penalties and potential reputational damage.
  • Broader market volatility and sector-specific rotation could impact Amgen's stock price, independent of its fundamental performance.

Upcoming Catalysts

  • Top-line results from the Phase 3 MariTide trials will be the primary catalyst for re-rating the company's growth potential in the obesity market.
  • Future earnings reports will be critical to assess the impact of competition on Tepezza and other key revenue drivers.
  • Any further developments or finalization of the securities litigation settlement will provide clarity on potential financial liabilities.
  • Strategic capital allocation decisions, such as M&A activity or changes to the dividend policy, could influence investor sentiment and valuation.

Upcoming Events

No verified update available

Last Updated

Sources and verification

Each generated research claim remains linked to its supporting update. Primary evidence comes from filings, company materials, or regulators; secondary evidence provides additional context.

  • Published stock briefSecondary sourceAnalyst OpinionInvestors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Zacks Investment Research · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceSocial Signal@Amgen - X · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceSocial Signal🇿🇦 Jayden Schaper (Alfred Dunhill Championship) 🇿🇦 Casey Jarvis (Investec South African Open Championship) 🇩🇰 Jeff Winther (Danish Golf Championship) 🏴󠁧󠁢󠁳󠁣󠁴󠁿 Scott Jamieson (Nexo Golf Championship) 🇮🇪 Shane Lowry (Amgen Irish Open) 🏴󠁧󠁢󠁥󠁮󠁧󠁿 Joe Dean ( - X · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceAnalyst OpinionInvestors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Zacks Investment Research · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
  • Published stock briefSecondary sourceSocial SignalEvery shot of Shane Lowry's final three holes as he went on to win the 2026 Amgen Irish Open by 11 shots 🏆 - X · Published 2026-11-21 01:01:39Open verification sourceSupports: Published stock brief
Market-data attributionYahoo Finance delayed market data · provider detailsMarket prices are supporting signals only and do not establish the research conclusion.

Community View

Sign in with Google to vote once per stock.

Bullish
Bearish
Neutral

Total votes: 0

Disclaimer

The Hedge Book provides AI-assisted educational market research. It is not a registered investment adviser, broker, dealer, or financial planner. Content may contain errors and should be independently verified. Do not treat this page as personalized advice to buy, sell, or hold any security.